A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

被引：0
作者：
Tetsuhiko Asao
Satoshi Watanabe
Takahiro Tanaka
Satoshi Morita
Kunihiko Kobayashi
机构：
[1] Juntendo University Graduate School of Medicine,Department of Respiratory Medicine
[2] Niigata University Graduate School of Medical and Dental Sciences,Department of Respiratory Medicine and Infectious Diseases
[3] Niigata University Medical and Dental Hospital,Clinical and Translational Research Center
[4] Kyoto University Graduate School of Medicine,Department of Biomedical Statistics and Bioinformatics
[5] Saitama Medical University International Medical Center,Department of Respiratory Medicine
来源：
BMC Cancer | / 22卷
关键词：
Small-cell lung cancer; Poor performance status; Immune checkpoint inhibitor; Anti-PD-L1; Durvalumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 49 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]  
Ferlay J(2020)The effect of advances in lung-Cancer treatment on population mortality N Engl J Med 383 640-649
[3]  
Soerjomataram I(2002)Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 85-91
[4]  
Siegel RL(1992)Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the southeastern Cancer study group J Clin Oncol 10 282-291
[5]  
Torre LA(2006)Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24 2038-2043
[6]  
Jemal A(2009)Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 J Clin Oncol 27 2530-2535
[7]  
Howlader N(2016)Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer Lung Cancer (Auckl) 7 35-44
[8]  
Forjaz G(2007)Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 Br J Cancer 97 162-169
[9]  
Mooradian MJ(2020)Immunotherapeutic approaches for small-cell lung cancer Nat Rev Clin Oncol 17 300-312
[10]  
Noda K(2019)Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Lancet 394 1929-1939
12345